Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines

Boliukh, Iryna; Rombel‐Bryzek, Agnieszka; Radecka, Barbara

doi:10.5603/njo.a2022.0024

Cited by 3 publications

(7 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the immunoadjuvant property of HSPs elicits non-specific immune responses, as well. By virtue of all these features, the HSP-TAA complexes could be considered as a suitable component in development of HPV therapeutic vaccine [ 3 ]. Several HSP-based vaccines are underway to analyze the antigenic or adjuvant properties of HSPs [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

“…Heat shock proteins (HSPs) are one of the cytoprotective factors and potent cell buffering systems that are overexpressed under extrinsic or intrinsic stressors [ 1 , 2 ]. They protect cell homeostasis through binding to a variety of proteins leading to the maintenance of their structural and functional integrity [ 3 ]. HSPs are highly conserved proteins with more than 50% sequence similarity from bacteria to eukaryotes [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

“…Because of the immunogenic properties of HSP families, they can be used as antigens, chaperones or natural adjuvants alone, or fused to other proteins in development of therapeutic vaccines [ [8] , [9] , [10] ]. HSP-based therapeutic vaccines improve the uptake of tumor antigen by antigen-presenting cells (APCs), and potentially stimulate the immune system [ 3 , 5 , 7 , 11 , 12 ]. Generally, they can activate cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs) and B-lymphocytes, and also stimulate the natural killer (NK) cells and macrophages [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…HSP-based therapeutic vaccines improve the uptake of tumor antigen by antigen-presenting cells (APCs), and potentially stimulate the immune system [ 3 , 5 , 7 , 11 , 12 ]. Generally, they can activate cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs) and B-lymphocytes, and also stimulate the natural killer (NK) cells and macrophages [ 3 ]. The anti-cancer therapeutic vaccine can be developed by the HSP-TAA (tumor associated antigens) complexes isolated from the patient's body or made in the ex-vivo conditions [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…Generally, they can activate cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs) and B-lymphocytes, and also stimulate the natural killer (NK) cells and macrophages [ 3 ]. The anti-cancer therapeutic vaccine can be developed by the HSP-TAA (tumor associated antigens) complexes isolated from the patient's body or made in the ex-vivo conditions [ 3 ]. The studies indicated that the interaction of Hsp27 with TLRs induces signaling pathway to activate nuclear factor-kappa B (NF-κB), dendritic cell (DC) maturation, and finally secretion of Th1-type cytokines [ [13] , [14] , [15] ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Immunoinformatics studies of heat shock proteins 27 and 70: Development of potent therapeutic vaccine constructs against human papillomavirus-related cancers

Rezaei,

Namvar,

Akbari

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immunoinformatics studies of heat shock proteins 27 and 70: Development of potent therapeutic vaccine constructs against human papillomavirus-related cancers

Rezaei,

Namvar,

Akbari

et al. 2023

Heliyon

View full text Add to dashboard Cite

Comparison of Adjuvant Effects of Montanide ISA-720 and Heat Shock Protein 27 in Increasing Immunostimulatory Properties of HIV-1 Nef-Vif Fusion Protein Construct

Khairkhah

Shahhosseini

Agi

et al. 2023

PPL

View full text Add to dashboard Cite

Aim: Effective T-cell-mediated immunity has emerged as an essential component of human immunodeficiency virus-1 (HIV-1) vaccination. Thus, inducing an immune response against HIV proteins such as Nef and Vif, two major accessory proteins with critical roles in HIV pathogenesis and immune evasion, may lead to an effective approach. background: Effective T-cell-mediated immunity has emerged as an essential component of human immunodeficiency virus-1 (HIV-1) vaccination. Thus, inducing an immune response against HIV proteins such as Nef and Vif, two major accessory proteins with critical roles in HIV pathogenesis and immune evasion, may lead to an effective approach Introduction: Our goal is to evaluate and compare Montanide ISA-720 and heat shock protein 27 in increasing immunostimulatory properties of HIV-1 Nef-Vif fusion protein as a vaccine candidate. objective: Our goal is to evaluate and compare Montanide ISA-720 and heat shock protein 27 in increasing immunostimulatory properties of HIV-1 Nef-Vif fusion protein as a vaccine candidate. Methods: In this study, the nef-vif fusion gene with and without the heat shock protein 27 (hsp27) gene was cloned in the prokaryotic pET24a (+) vector. Then, the recombinant Nef-Vif and Hsp27-Nef-Vif proteins were generated in the E. coli system. Finally, their immunostimulatory properties were evaluated in mice. Indeed, the potency of Hsp27 as an endogenous natural adjuvant was investigated to enhance HIV-1 Nef-Vif antigen-specific immunity compared to Montanide ISA-720 as a commercial adjuvant in protein-based immunization strategy. method: In this study, the nef-vif fusion gene with and without the heat shock protein 27 (hsp27) gene was cloned in prokaryotic pET24a (+) vector. Then, the recombinant Nef-Vif and Hsp27-Nef-Vif proteins were generated in E. coli system. Finally, their immunostimulatory properties were evaluated in mice. Indeed, the potency of Hsp27 as an endogenous natural adjuvant was investigated to enhance HIV-1 Nef-Vif antigen-specific immunity as compared to Montanide ISA-720 as a commercial adjuvant in protein-based immunization strategy. Results: Our results approved the role of Hsp27 as an effective adjuvant in the stimulation of B- and T-cell immunity. The linkage of Hsp27 to antigen could elicit higher levels of IgG1, IgG2a, IFN-γ, IL-5 and Granzyme B than antigen mixed with Montanide ISA-720. Moreover, the ratios of IFN-γ/ IL-5 and IgG2a/ IgG1 were significantly increased in groups receiving Nef-Vif protein + Montanide ISA-720 and Hsp27-Nef-Vif protein indicating the direction of the immune response pathway toward strong Th1 response. These ratios were higher in the group receiving Hsp27-Nef-Vif protein than in the group receiving Nef-Vif protein + Montanide ISA-720. Conclusion: Our findings suggest that Hsp27 can be used as an effective adjuvant to enhance antigen-specific immune responses in HIV-1 infectious models for therapeutic vaccine development. other: -

show abstract

Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence

Pietkiewicz,

Zaborowski,

Jaz

et al. 2023

IJMS

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecological cancer worldwide. Classifying endometrial cancer into low- or high-risk groups based on the following features is recommended: tumor grade, lymphovascular space invasion, myometrial involvement, and non-endometrioid histology. Despite the recent progress in molecular profiling of endometrial cancer, a substantial group of patients are misclassified based on the current criteria. This study aimed to identify proteins that could be used as biomarkers for the stratification of endometrial cancer patients into low- or high-risk groups. The proteomic analysis of serum samples from endometrial cancer patients was performed using matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF MS). The data were then analyzed using chemometric algorithms to identify potential biomarkers. Nineteen precursor ions were identified as fragments of eighteen proteins which included (1) connective tissue matrix proteins, (2) cytoskeletal proteins, and (3) innate immune system molecules and stress proteins. These biomarkers could be used to stratify the high- and low-risk patients, thus enabling more precise treatment decisions.

show abstract

Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines

Cited by 3 publications

References 83 publications

Immunoinformatics studies of heat shock proteins 27 and 70: Development of potent therapeutic vaccine constructs against human papillomavirus-related cancers

Immunoinformatics studies of heat shock proteins 27 and 70: Development of potent therapeutic vaccine constructs against human papillomavirus-related cancers

Comparison of Adjuvant Effects of Montanide ISA-720 and Heat Shock Protein 27 in Increasing Immunostimulatory Properties of HIV-1 Nef-Vif Fusion Protein Construct

Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence

Contact Info

Product

Resources

About